Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
BioNxt Solutions Inc. says it is advancing its proprietary sublingual everolimus oral dissolving film (ODF) for organ transplant rejection, and has initiated a large-animal pharmacokinetic study.
BioNxt is advancing its sublingual everolimus ODF for organ transplant rejection and has initiated a large-animal pharmacokinetic study.